CL2012002613A1 - Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular. - Google Patents

Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.

Info

Publication number
CL2012002613A1
CL2012002613A1 CL2012002613A CL2012002613A CL2012002613A1 CL 2012002613 A1 CL2012002613 A1 CL 2012002613A1 CL 2012002613 A CL2012002613 A CL 2012002613A CL 2012002613 A CL2012002613 A CL 2012002613A CL 2012002613 A1 CL2012002613 A1 CL 2012002613A1
Authority
CL
Chile
Prior art keywords
cyclopentyladenosine
intraocular pressure
compound
pharmaceutical composition
anterior chamber
Prior art date
Application number
CL2012002613A
Other languages
English (en)
Spanish (es)
Inventor
William K Mcvicar
Prakash Jagtap
Norman N Kim
Thomas G Mccauley
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of CL2012002613A1 publication Critical patent/CL2012002613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2012002613A 2010-03-26 2012-09-21 Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular. CL2012002613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31810510P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
CL2012002613A1 true CL2012002613A1 (es) 2012-12-21

Family

ID=44673656

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002613A CL2012002613A1 (es) 2010-03-26 2012-09-21 Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.

Country Status (16)

Country Link
US (4) US8476247B2 (enExample)
EP (1) EP2569325A4 (enExample)
JP (2) JP2013523739A (enExample)
KR (1) KR20130029050A (enExample)
CN (1) CN102933593A (enExample)
AU (1) AU2011230580A1 (enExample)
BR (1) BR112012023749A2 (enExample)
CA (1) CA2792266A1 (enExample)
CL (1) CL2012002613A1 (enExample)
CO (1) CO6630141A2 (enExample)
EA (1) EA201290958A1 (enExample)
MX (1) MX2012010724A (enExample)
PH (1) PH12012501906A1 (enExample)
SG (1) SG184221A1 (enExample)
WO (1) WO2011119969A1 (enExample)
ZA (1) ZA201207090B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012017106A2 (pt) * 2010-01-11 2018-05-29 Inotek Pharmaceuticals Corp combinação, kit e método de redução de pressão intraocular.
JP2013523739A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
NZ627778A (en) * 2012-01-26 2017-01-27 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
AU2014239222A1 (en) 2013-03-15 2015-10-01 Inotek Pharmaceuticals Corporation Ophthalmic formulations
JP2018501219A (ja) * 2014-12-03 2018-01-18 イノテック ファーマシューティカルズ コーポレイション 黄斑変性の予防、軽減または治療方法
KR20250025414A (ko) * 2022-06-17 2025-02-21 상하이 센후이 메디슨 컴퍼니 리미티드 시클로펜틸아데노신 유도체 및 이의 약학적 용도

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (enExample) 1970-12-28 1974-09-25
CH563405A5 (enExample) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4849311A (en) 1986-09-24 1989-07-18 Toa Nenryo Kogyo Kabushiki Kaisha Immobilized electrolyte membrane
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0569046B1 (en) 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
HU212570B (en) 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DK62692D0 (enExample) 1992-05-14 1992-05-14 Novo Nordisk As
WO1994002497A1 (en) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5338430A (en) 1992-12-23 1994-08-16 Minnesota Mining And Manufacturing Company Nanostructured electrode membranes
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
ATE206432T1 (de) 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2289731A1 (en) 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
JP2001519386A (ja) 1997-10-15 2001-10-23 トーマス・ジェファーソン・ユニバーシティ 哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2775901B1 (fr) 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CA2337499A1 (en) 1998-07-16 2000-01-27 The Trustees Of The University Of Pennsylvania Methods for reducing intraocular pressure using a3-adenosine antagonists
EP1121372B1 (en) 1998-10-16 2006-06-28 Pfizer Limited Adenine derivatives
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
JP2003502434A (ja) 1999-06-22 2003-01-21 スィーヴィー セラピューティクス インコーポレイテッド チオフェンａ２ａ受容体アゴニスト
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
CN1450896A (zh) 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
BR0206492A (pt) 2001-01-16 2004-02-10 Can Fite Biopharma Ltd Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
JP2004537401A (ja) 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
CA2460911C (en) 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
NZ536001A (en) 2002-04-18 2006-05-26 Cv Therapeutics Inc Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
MXPA04009471A (es) 2002-04-30 2005-01-25 Alcon Inc Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas.
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004056180A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery (1)
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP1718286A4 (en) 2004-01-22 2010-03-31 Nicox Sa NITROSIS AND / OR NITROSYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
PT1758596E (pt) 2004-05-26 2010-06-23 Inotek Pharmaceuticals Corp Derivados de purina como agonistas do receptor de adenosina a1 e processos para a sua utilização
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CA2573682A1 (en) 2004-07-12 2006-02-16 Cv Therapeutics, Inc. Process for the preparation of a1 adenosine receptor agonists
US20090220516A1 (en) 2005-06-22 2009-09-03 Alan Laties Neuroprotection of retinal ganglion cells
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
WO2008029276A2 (en) 2006-02-02 2008-03-13 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP2009530393A (ja) 2006-03-23 2009-08-27 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
EP2076267A4 (en) * 2006-10-06 2013-07-31 Univ Pennsylvania EFFECTIVE DELIVERY OF CROSS SPECIES A3 ADENOSINE RECEPTOR ANTAGONISTS TO REDUCE AUGENIN PRESSURE
ATE513470T1 (de) 2006-11-10 2011-07-15 Basf Se Kristalline fipronil-modifikation
CA2671613C (en) 2006-12-05 2018-07-03 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of trk receptor modulators
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
EP2205071B1 (en) 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
JP2011511802A (ja) 2008-02-07 2011-04-14 ギリアード・パロ・アルト・インコーポレイテッド Ａｂｃａ−１を上昇させる化合物およびかかる化合物の使用方法
WO2010056981A2 (en) 2008-11-13 2010-05-20 Massachusetts General Hospital Methods and compositions for regulating iron homeostasis by modulation bmp-6
KR101757940B1 (ko) 2009-05-01 2017-07-13 이노텍 파마슈티컬스 코포레이션 인간 안압을 감소시키는 방법
CN102665730A (zh) * 2009-10-26 2012-09-12 伊诺泰克制药公司 眼用制剂及其制造方法
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
BR112012017106A2 (pt) 2010-01-11 2018-05-29 Inotek Pharmaceuticals Corp combinação, kit e método de redução de pressão intraocular.
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
HUE031529T2 (en) * 2010-03-19 2017-07-28 Inotek Pharmaceuticals Corp Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure
JP2013522323A (ja) 2010-03-19 2013-06-13 イノテック ファーマシューティカルズ コーポレイション 眼内圧を下げるためのアデノシンＡ１受容体アゴニストと非選択的β−アドレナリン受容体遮断薬との組合せ組成物
SG184223A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Adenosine compounds and their use thereof
JP2013523739A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
NZ627778A (en) 2012-01-26 2017-01-27 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
AU2014239222A1 (en) * 2013-03-15 2015-10-01 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CN105188713A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 提供眼部神经保护的方法

Also Published As

Publication number Publication date
US20150080330A1 (en) 2015-03-19
EA201290958A1 (ru) 2013-04-30
AU2011230580A1 (en) 2012-10-11
US8476247B2 (en) 2013-07-02
SG184221A1 (en) 2012-10-30
MX2012010724A (es) 2012-11-12
CA2792266A1 (en) 2011-09-29
WO2011119969A1 (en) 2011-09-29
US20140018314A1 (en) 2014-01-16
JP2013523739A (ja) 2013-06-17
BR112012023749A2 (pt) 2016-08-23
KR20130029050A (ko) 2013-03-21
CN102933593A (zh) 2013-02-13
US20160158268A1 (en) 2016-06-09
US8895530B2 (en) 2014-11-25
US20110245195A1 (en) 2011-10-06
EP2569325A4 (en) 2013-10-09
ZA201207090B (en) 2014-03-26
US9289383B2 (en) 2016-03-22
EP2569325A1 (en) 2013-03-20
PH12012501906A1 (en) 2013-01-14
CO6630141A2 (es) 2013-03-01
JP2016147918A (ja) 2016-08-18

Similar Documents

Publication Publication Date Title
CR20140185A (es) Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio
CL2012002613A1 (es) Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.
MX2018005268A (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
SV2018005656A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene
GT201300153A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina
GT200700064A (es) Agonistas de ep2
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
GT201200243A (es) Derivados de pirazol como inhibidores de jak
ECSP14013215A (es) Compuestos novedosos
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
NI201400042A (es) 2 - tiopirimidinonas
AR059555A1 (es) Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
CL2012001352A1 (es) Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras.
CL2011002258A1 (es) Compuestos derivados heterociclicos fusionados; composicion farmaceutica que los comprende; y uso de los compuestos para tratar vih.
SV2018005657A (es) "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
GT201200213A (es) Combinacion triple para reducción de presion intraocular
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia